Full Product Name
VAPB siRNA (Rat)
Product Synonym Names
Vesicle-associated membrane protein-associated protein B; VAMP-B; VAMP-associated protein B; VAP-B
Product Gene Name
VAPB sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9Z269
Specificity
VAPB siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat VAPB gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of VAPB sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
VAPB sirna
siRNA to inhibit VAPB expression using RNA interference
Applications Tested/Suitable for VAPB sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for VAPB. It may not necessarily be applicable to this product.
NCBI Accession #
NP_068619.1
[Other Products]
NCBI GenBank Nucleotide #
NM_021847.3
[Other Products]
UniProt Primary Accession #
Q9Z269
[Other Products]
UniProt Related Accession #
Q9Z269[Other Products]
Molecular Weight
26,916 Da
NCBI Official Full Name
vesicle-associated membrane protein-associated protein B
NCBI Official Synonym Full Names
VAMP (vesicle-associated membrane protein)-associated protein B and C
NCBI Official Symbol
Vapb [Similar Products]
NCBI Protein Information
vesicle-associated membrane protein-associated protein B
UniProt Protein Name
Vesicle-associated membrane protein-associated protein B
Protein Family
Virulence-associated protein
UniProt Gene Name
Vapb [Similar Products]
UniProt Synonym Gene Names
VAMP-B; VAMP-associated protein B; VAP-B [Similar Products]
UniProt Entry Name
VAPB_RAT
NCBI Summary for VAPB
may play a role in exocytosis of neurotransmitters [RGD, Feb 2006]
UniProt Comments for VAPB
VAPB: Participates in the endoplasmic reticulum unfolded protein response (UPR) by inducing ERN1/IRE1 activity. Involved in cellular calcium homeostasis regulation. Defects in VAPB are the cause of amyotrophic lateral sclerosis type 8 (ALS8). ALS8 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms. Defects in VAPB are a cause of spinal muscular atrophy proximal ***** autosomal dominant (SMAPAD); also called late-onset spinal muscular atrophy Finkel type. A form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMAPAD is characterized by proximal muscle weakness that begins in the lower limbs and then progresses to upper limbs, onset in late *****hood (after third decade) and a benign course. Most of the patients remain ambulatory 10 to 40 years after clinical onset. Belongs to the VAMP-associated protein (VAP) (TC 9.B.17) family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral
Cellular Component: Golgi membrane; Golgi apparatus; endoplasmic reticulum membrane; membrane; endoplasmic reticulum; integral to membrane
Molecular Function: enzyme binding; protein homodimerization activity; FFAT motif binding; protein heterodimerization activity; microtubule binding; beta-tubulin binding
Biological Process: cellular calcium ion homeostasis; endoplasmic reticulum organization and biogenesis; ER to Golgi vesicle-mediated transport; unfolded protein response, activation of signaling protein activity; positive regulation of viral genome replication; unfolded protein response; virus-host interaction; negative regulation of viral protein levels in host cell
Research Articles on VAPB
1. YIF1A interacts with VAPB via its transmembrane regions, recycles between the ER and Golgi and is mainly localized to the ER-Golgi intermediate compartments in hippocampal neurons.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
